Case framing at a high level
The first analysis produced an intuitively attractive story: rare-disease genes were enriched in activated monocytes, suggesting an innate-immune mechanism. The problem was that the same state also carried interferon, stress, and sample-processing signatures observed across unrelated conditions. Magnitude alone could not distinguish specificity.
We changed the question from “is the module enriched?” to “what part of the module cannot be explained by common activation?” This made negative controls a primary analytical layer instead of a supplementary figure.
Negative-control library
The control library included type I and type II interferon response, NF-kB-associated inflammatory activation, immediate-early response, heat shock, oxidative stress, hypoxia, apoptosis, cell cycle, ribosomal and mitochondrial quality shifts, and dissociation-associated programs. Each signature retained its source, context, gene identifiers, direction, and known limitations.
Controls were scored with the same method and background used for the target module. This symmetry matters: a target tested with a favorable scoring method and controls tested differently do not provide a valid specificity comparison. Overlap was decomposed rather than removed indiscriminately because common inflammatory pathways can be part of genuine disease biology.
Donor and state model
Counts were aggregated within donor-by-state strata, and donor remained the unit of inference. Cell number entered as a precision and quality variable, not as the sample size. State abundance and within-state differential expression were estimated separately to distinguish recruitment or expansion from transcriptional remodeling.
Where metadata permitted, age, sex, disease context, stimulation, processing batch, and collection protocol were included as design variables or used for stratified sensitivity analyses. Analyses with unresolved confounding were labeled as transportability tests rather than causal contrasts.
Signal decomposition
The target score was modeled against the control-signature matrix, and the residual was inspected for multi-gene coherence. Regression residuals, matched resampling, and leading-edge overlap provided complementary views. No single residualization method was allowed to define the conclusion.
The raw monocyte enrichment decreased substantially after generic activation components were accounted for. The remaining signal was smaller but more stable across references and less correlated with global RNA quality, cell cycle, or interferon intensity. Several canonical activation genes left the leading edge, while a bounded set of target-linked genes remained coordinated.
Specificity and alternative explanations
The residual was compared with expression-matched random modules and tested in unrelated inflammatory contexts. It did not behave as a universal marker of all activated monocytes, but neither was it exclusive to one rare-disease label. We therefore interpret it as a candidate mechanistic state shared by a narrower set of immune perturbations.
Medication, infection, tissue compartment, and unrecorded processing remain plausible alternatives. The analysis cannot eliminate them from public data. It can show that the conclusion no longer depends entirely on the most common technical and inflammatory programs.
Experimental decision
The resulting experiment uses a factorial design: genotype or gene perturbation crossed with disease-relevant stimulation and generic interferon or stress controls. The readout panel includes the residual module, cytokine secretion, viability, differentiation state, and a function linked to the nominated mechanism.
A mechanism-specific result should alter the residual program and functional readout without simply reproducing global stress or suppressing all inflammatory signaling. Genetic correction or pathway-specific rescue should reverse the residual component. If only generic activation changes, the rare-disease interpretation should be rejected or narrowed.
What the analysis establishes
The original signal was overbroad
Common interferon, stress, and processing programs explained much of the raw enrichment.
A smaller residual reproduced
A multi-gene component remained coordinated in a bounded monocyte state across independent references.
Specificity improved as magnitude decreased
The reduction in score represented removal of generic explanations, not loss of the central hypothesis.
The experiment changed materially
The final design tests disease-relevant and generic stimuli side by side and requires rescue of the residual.
What we conclude
We conclude that the raw activated-monocyte signal is not sufficiently specific to support a rare-disease mechanism. After explicit decomposition, a smaller residual program remains credible as a research hypothesis because it is multi-gene, donor-aware, and transferable across references.
The residual must now earn causal status experimentally. A factorial perturbation with matched stress and interferon controls, functional readouts, and rescue can determine whether it represents a disease-linked immune state or another broadly inducible response.
Limitations
- Public immune references contain incomplete covariate and treatment metadata.
- Residualization can remove true biology when common inflammatory pathways are mechanistically central.
- Peripheral immune states may not reproduce tissue-resident or disease-site biology.
- The case demonstrates evidence refinement, not clinical subgroup discovery.